Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Arlene O Siefker-Radtke

Showing results (1-10 of 82) with videos related to

Pageof 9
Sort By:
Expert Review of Anticancer Therapy|December 4, 2009
Surgical consolidation of initially unresectable urothelial carcinoma: an incremental opportunity to cureArlene O Siefker-Radtke
The Lancet. Oncology|December 15, 2023
Evolution of front-line immunotherapy for metastatic urothelial cancerArlene O Siefker-Radtke, Monica Desai
American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists|February 11, 2022
Erdafitinib for locally advanced or metastatic urothelial carcinomaArlene O Siefker-Radtke, Yohann Loriot
The Lancet. Oncology|December 16, 2014
Towards effective adjuvant treatment for urothelial cancerArlene O Siefker-Radtke, Jianjun Gao
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 5, 2017
Reply to B. Biswas et alArlene O Siefker-Radtke, Matthew T Campbell
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 7, 2017
Now Is the Time for Perioperative Chemotherapy in Upper Tract Urothelial CancerArlene O Siefker-Radtke, Matthew T Campbell
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 25, 2023
Combinations, Sequencing, and the Contribution of Components: New Frontline Standards for Metastatic Urothelial CarcinomaArlene O Siefker-Radtke, Diana Cauley, Omar Alhalabi
The New England Journal of Medicine|October 17, 2019
Erdafitinib in Urothelial Carcinoma. ReplyYohann Loriot, Andrea Necchi, Arlene O Siefker-Radtke
Future Oncology (London, England)|November 2, 2023
Plain language summary of erdafitinib in locally advanced or metastatic urothelial carcinoma: a phase 2 study with long-term follow-upYohann Loriot, Anne O'Hagan, Arlene O Siefker-Radtke
Cancer Journal (Sudbury, Mass.)|April 26, 2016
The State of Immune Checkpoint Inhibition in Urothelial Carcinoma: Current Evidence and Future Areas of ExplorationMatthew T Campbell, Arlene O Siefker-Radtke, Jianjun Gao
Pageof 9

Showing results (1-10 of 82) with videos related to

Sort By:
Pageof 9
Expert Review of Anticancer Therapy|December 4, 2009
Surgical consolidation of initially unresectable urothelial carcinoma: an incremental opportunity to cureArlene O Siefker-Radtke
The Lancet. Oncology|December 15, 2023
Evolution of front-line immunotherapy for metastatic urothelial cancerArlene O Siefker-Radtke, Monica Desai
American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists|February 11, 2022
Erdafitinib for locally advanced or metastatic urothelial carcinomaArlene O Siefker-Radtke, Yohann Loriot
The Lancet. Oncology|December 16, 2014
Towards effective adjuvant treatment for urothelial cancerArlene O Siefker-Radtke, Jianjun Gao
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 5, 2017
Reply to B. Biswas et alArlene O Siefker-Radtke, Matthew T Campbell
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 7, 2017
Now Is the Time for Perioperative Chemotherapy in Upper Tract Urothelial CancerArlene O Siefker-Radtke, Matthew T Campbell
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 25, 2023
Combinations, Sequencing, and the Contribution of Components: New Frontline Standards for Metastatic Urothelial CarcinomaArlene O Siefker-Radtke, Diana Cauley, Omar Alhalabi
The New England Journal of Medicine|October 17, 2019
Erdafitinib in Urothelial Carcinoma. ReplyYohann Loriot, Andrea Necchi, Arlene O Siefker-Radtke
Future Oncology (London, England)|November 2, 2023
Plain language summary of erdafitinib in locally advanced or metastatic urothelial carcinoma: a phase 2 study with long-term follow-upYohann Loriot, Anne O'Hagan, Arlene O Siefker-Radtke
Cancer Journal (Sudbury, Mass.)|April 26, 2016
The State of Immune Checkpoint Inhibition in Urothelial Carcinoma: Current Evidence and Future Areas of ExplorationMatthew T Campbell, Arlene O Siefker-Radtke, Jianjun Gao
Pageof 9